ELDN

Eledon Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 3/10
  • Momentum↓ 4/10
Eledon Pharmaceuticals sales and earnings growth
ELDN Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -157.45%
  • FCF Y/Y↓ -79.71%
Eledon Pharmaceuticals gross and profit margin trends
ELDN Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -56.80%
Eledon Pharmaceuticals net debt vs free cash flow
ELDN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Eledon Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗